Individual case analysis with 55 patients and 74 skin lesions showed a 78% clinical response rate for cSCC, 70% for BCC, and 71% for AK, with complete remission rates of 56%, 35%, and 15% respectively.
VALE application led to shorter times to best clinical response for cSCC and BCC. Adverse reactions, including erythema, were moderate, with therapy mostly continuing uninterrupted despite occasional pauses.
Collection
[
|
...
]